Clinical trials: Cyclophosphamide, completed
Brain and Central Nervous System Tumors
Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003859
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Breast Cancer
Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.
2 different treatment schedules may be used for neoadjuvant chemotherapy in breast cancer using adriamycin, cyclophosphamide and taxotere. The most optimal sequence- concurrent or sequential- is however unclear.
- Trial name
- INTENS (NCT00314977)
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 24 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Radboud University Medical Center
Solid Tumors, Advanced Cancer
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
The goal of this clinical research study is to find the highest safe dose of AMG 531 that will decrease the risk and severity of thrombocytopenia (low platelet counts) in patients who have received chemotherapy.
- Trial name
- NCT00147225
- Testing
- AMG 531, Carboplatin, Adriamycin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003050
- Testing
- cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Southern California
Breast Cancer
S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897091
- Testing
- comparative genomic hybridization, microarray analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- SWOG Cancer Research Network
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002838
- Testing
- Filgrastim (G-CSF), Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)-specific T-cell response after vaccination. The primary purpose of this study is to ascertain whether vaccination with tecemotide (L-BLP25) induces a…
- Trial name
- NCT01094548
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer, Neutropenia
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Conditions
- Breast Cancer, Neutropenia, Febrile Neutropenia
- Trial name
- NCT02119715
- Testing
- Pegylated rhG-CSF 100μg/kg, Pegylated rhG-CSF:150 μg/kg, rhG-CSF 5 μg/kg/day
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Multiple Myeloma, Non-Hodgkin-Lymphoma
Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation
A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and…
- Conditions
- Multiple Myeloma, Non-Hodgkin-Lymphoma, Hodgkin's Disease
- Trial name
- OCTET-CY (NCT01283776)
- Testing
- Cyclophosphamide
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- University of Cologne
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia…
- Trial name
- NCT02953340
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 237 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Lymphoma, Large B-Cell, Diffuse
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- ROBUST (NCT02285062)
- Testing
- lenalidomide, Rituximab, Cyclophosphamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 570 people
- Sponsor
- Celgene
Lupus Nephritis
A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt
The aim of this study is to conduct a pharmacoeconomic analysis to compare the use of Mycophenolate Mofetil or i.v. Cyclophosphamide as induction therapy from a third party payer perspective in LN patients in the Egyptian context
- Trial name
- NCT05195086
- Testing
- endoxan, cellcept
- Where
- Egypt
- Volunteers
- 122 people
- Sponsor
- Nada Magdy Mansour
Unspecified Childhood Solid Tumor, Protocol Specific
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
RATIONALE: Thalidomide may kill tumor cells by stopping the growth of new blood vessels to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003754
- Testing
- cyclophosphamide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for…
- Trial name
- NCT00199056
- Testing
- Dexamethasone / Prednisolone, Cyclophosphamide, Methotrexate
- Where
- Germany
- Volunteers
- 225 people
- Sponsor
- Goethe University
Breast Cancer, Obesity
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
To determine the effect of weight on doxorubicin and cyclophosphamide plasma clearance in participants who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese (BMI 25-34.9 kg/m2), or class II-III…
- Trial name
- NCT01537029
- Testing
- Doxorubicin, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Texas Tech University Health Sciences Center
Lymphocytic Leukemia, Chronic
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.
- Trial name
- NCT02533401
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 9 sites in Argentina, Venezuela
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors.
- Trial name
- NCT00039481
- Testing
- oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and vincristine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00726700
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Volunteers
- 109 people
- Sponsor
- Universität des Saarlandes
Scleroderma, Systemic, Sclerosis
Scleroderma: Cyclophosphamide or Transplantation
SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation.
- Conditions
- Scleroderma, Systemic, Sclerosis, Autoimmune Disease
- Trial name
- SCOT (NCT00114530)
- Testing
- mHSCT, cyclophosphamide
- Where
- 17 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Lymphocytic Leukemia (CLL)
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a…
- Trial name
- CRISTALLO (NCT04285567)
- Testing
- Obinutuzumab, Venetoclax, Fludarabine
- Where
- 40 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.